Trial Profile
A phase IV, randomized, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety and tolerability of CSL Limited's influenza virus vaccine in adults aged greater than or equal to 18 to less than 65 years.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Oct 2016
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Afluria) (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors CSL; Seqirus
- 29 Aug 2016 Results published in the Vaccine.
- 24 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov